Head and Neck Cancers (Issue 4) | Special Reports

Patient-Derived Xenografts Could Personalize Anaplastic Thyroid Cancer Care

February 17, 2016

Clinical Articles

Anaplastic thyroid cancer is an extremely aggressive form of cancer that cannot be cured by surgery and has a median survival of about 6 months. The malignancy normally occurs in patients over the age of 60, and there is not a standard of care, according to John A. Copland III, PhD, professor, Cancer Biology, Mayo Clinic.

Dr. Sylvia Asa on Treating Different Types of Thyroid Cancer

February 16, 2016

Clinical Articles

Asa says one of the most common mutations in subtypes of thyroid cancer is the BRAF mutation. She adds that while the mutation is common, a good number of patients do not respond to BRAF-targeted therapies, hinting that these subtypes are more complex than previously thought.

Link Drawn Between Oral HPV and Risk of Head and Neck Cancers

February 16, 2016

Clinical Articles

Patients with a certain type of oral human papilloma virus (HPV) have an increased risk of developing head and neck squamous cell carcinoma, as well as oropharyngeal cancer, according to a new study.

Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid Cancer

February 16, 2016

Clinical Articles

Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.

Nivolumab Could Change Head and Neck Cancer Treatment Paradigm

February 16, 2016

Clinical Articles

With the phase III CheckMate-141 trial being stopped early due to the anti-PD-1 agent nivolumab having met its primary endpoint of overall survival improvement in head and neck cancer, Robert Ferris, MD, PhD, couldn't be more elated.

Nivolumab Boosts OS in Phase III in SCCHN Study

February 15, 2016

Clinical Articles

Anti–PD-1 agent nivolumab boosted overall survival versus an investigator's choice of therapy in platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) during a recent trial.